Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Panic disorder (PD) is a prevalent and disabling anxiety disorder that can be treated effectively. Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines are among the most frequently prescribed drugs for PD. In this article, the authors review the current evidence on efficacy, adverse events, and limitations of these two treatment options. AREAS COVERED: MEDLINE/Pubmed and Web of Science databases were searched for open or placebo-controlled trials on SSRIs and/or benzodiazepines in PD treatment. EXPERT OPINION: The literature search yielded 4,957 articles related to the theme. Of these, 24 articles were included in this review. Despite their usefulness in PD, SSRIs are associated with a delay of several weeks in onset of therapeutic effect and have the potential to exacerbate anxiety and panic early in the treatment course. Benzodiazepines present rapid onset of action, but can cause tolerance and dependence. Despite strong evidence of the effectiveness of SSRIs and benzodiazepines in the treatment of PD, few trials have performed head-to-head comparisons of these two drug classes. Future studies on the pharmacological treatment of PD should make direct comparisons of risks, benefits, and limitations of each group. This could help improve the evidence-based pharmacotherapy of PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Figure 1) [8].”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The spectrum of behaviors influenced by serotonin
Lucki, I. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00139-5 · Cited by 1,158 · cited 1×
“areas with its neuronal cell bodies in the brainstem raphe nuclei and widespread axonal projections to the forebrain regions [3].”
BackgroundNeuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004 · cited 1×
“[2], panic attacks originate from a dysfunction in the brain’s fear network that integrates various structures of the brainstem, amygdala, medial hypothalamus, and cortical regions.”
BackgroundMechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · cited 7×
“Increased serotonin in these areas may be responsible for the insomnia and sleep disruption seen with SSRIs [52].”
BackgroundInfluentialAddiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Hooked on benzodiazepines: GABAA receptor subtypes and addiction
Tan, K. R., Rudolph, U., & Lüscher, C. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.004 · Cited by 365 · cited 15×
“GABAA are ligand-gated chloride-selective ion channels that are physiologically activated by GABA, the main inhibitory neurotransmitter in the brain.”
BackgroundInfluentialAndrade, C., Sandarsh, S., Chethan, K. B., & Nagesh, K. S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05786blu · Cited by 302 · cited 1×
“Abnormal bleeding [68] and hyponatremia [69] are also associated with SSRI use.”
BackgroundLiu, B. A., Mittmann, N., Knowles, S. R., & Shear, N. H. (1996) · Europe PMC (PubMed Central) · Cited by 290
Research works printed but not linked: 6
- Association WGOPDAP, 1998, Am J Psychiatry, 155, 1
- Black K., 2000, J Psychiatry Neurosci, 25, 255
- Nardi AE, 2013, Curr Drug Targets, 14, 353
- Longo LP, 2000, Am Fam Physician, 61, 2121
- Bighelli I, 2016, Cochrane Lib
- Liu B.A., 1996, Can Med Assoc J, 155, 519
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“The subjects were interviewed with surgery-based consultations for approximately 10 min [12].”
BackgroundNasir, M., Trujillo, D., Levine, J. L. S., Dwyer, J. B., Rupp, Z. W., & Bloch, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.548505 · Cited by 107
“Long-term use of benzodiazepines can be associated with dependency (and thus reduced efficacy at a given dose), rebound anxiety, a discontinuation syndrome and memory impairment (15).”
BackgroundQuagliato, L. A., Cosci, F., Shader, R. I., Silberman, E. K., Starcevic, V., Balon, R., Dubovsky, S. L., Salzman, C., Krystal, J. H., Weintraub, S. J., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119859372 · Cited by 35
“In addition, the combination of SSRIs and BZs in the first weeks of PD treatment is recommended (Quagliato et al., 2018).”
BackgroundBeta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis
Archer, C., Wiles, N., Kessler, D. A., Turner, K. M., & Caldwell, D. M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.068 · Cited by 40
Shigetsura, Y., Imai, S., Endo, H., Shimizu, Y., Ueda, K., Murai, T., Itohara, K., Nakagawa, S., Yonezawa, A., Ikemi, Y., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000499 · Cited by 31
Metadata
- Authors
- Quagliato, L. A., Freire, R. C., & Nardi, A. E.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Laboratory of Panic & Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Corresponding author
- Quagliato, Laiana A.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2018-01-22
- Volume
- 17
- Issue
- 3
- Pages
- 315-324
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2794421769
- Cited by
- 62
- References
- 71
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 25 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 3
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- panic disorder, selective serotonin reuptake inhibitors, benzodiazepines, pharmacotherapy, drug efficacy, adverse drug reactions, benzodiazepine dependence, tolerance (pharmacology and immunology), head-to-head comparison
- MeSH terms
- Benzodiazepines, Drug Tolerance, Humans, Time Factors, Panic Disorder, Selective Serotonin Reuptake Inhibitors, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. https://app.cochat.ai/papers/10.1080/14740338.2018.1429403
- The paper
- Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018). Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2018.1429403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.